News and Press

By Genetic Engineering & Biotechnology News (GEN) | August 3, 2026 Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow. Sethera will generate and experimentally screen architecture-diverse polymacrocyclic peptide libraries. Receptor.AI will apply physics-based modeling, artificial intelligence, and multiparameter optimization to interpret sequence, architecture, enrichment, and activity data; develop binding hypotheses; prioritize candidate series; and […]

By Inayah Entzminger at ASBMB Today | July 9, 2026 Peptide drugs offer greater surface specificity than small molecules for therapeutic applications. Making them as stable in the body as small molecules remains a major challenge. Sethera Therapeutics, a peptide biotechnology company based in Salt Lake City, Utah, aims to solve a central challenge in

Partner Bio/Inveniv | June 24 Aaron is on the ground BIO International Convention (hosted by Biotechnology Innovation Organization), bringing Life Science conversations to life on the Partner Bio platform! (Soon to be Partner Bio app!) The discussion series leads off with CEO and Co-Founder of Sethera Therapeutics, Karsten Eastman, who has a nice “Pep Talk”

By By Ankit Kankar | June 22, 2026 Karsten Eastman, Co-founder and CEO of Sethera Therapeutics, discusses peptide therapeutics, translational discipline, precision oncology, and why the industry’s future will be defined by product credibility rather than platform promises. Cancer drug discovery is entering a more disciplined era. Investors, partners, and clinicians are increasingly focused on

by eHealth Radio and the Health News Channel | June 20, 2026 Karsten Eastman, CEO of Sethera Therapeutics whose discovery could be especially useful for enhancing GLP-1 medications such as semaglutide, the active ingredient in Ozempic and Wegovy, which are widely used to treat diabetes and obesity joins eHealth Radio and the Health News Channel.

By Talking Biotech | April 16, 2026 In this episode of the Talking Biotech podcast, Dr. Karsten Eastman discusses the significance of peptides in biology and their therapeutic potential. He explains the roles of peptides, particularly GLP-1 therapeutics, and the challenges associated with their stability and bioavailability. The conversation delves into nature’s strategies for enhancing

By Drug Development & Delivery | March/April The modern therapeutic toolbox has been dominated by two poles. Small molecules excel at oral dosing, distribution, and manufacturing, and they are superb when a target exposes deep, well defined pockets. Yet their very compactness, typically <600 Daltons, constrains the surface area they can contact, making it difficult

By Karsten Eastman | Feb 12, 2026 Generative AI has already changed what is possible in protein engineering. In the last few years, the field has moved from predicting protein structures to proposing entirely new proteins, often with experimentally verified folding and binding, at a pace that was unrealistic a decade ago. Much of that

By Pharma’s Almanac | February 2, 2026 Over the next decade, AI will continue to play an important and expanding role in biopharma, particularly in data integration, target identification, and optimization within well-charted chemical and biological spaces. That said, there remains a fundamental limitation: AI systems can only extrapolate from what has already been observed.

By Pharmaceutical Technology | January 20, 2026 Dr Karsten Eastman, CEO, Sethera Therapeutics, highlights the challenges around ‘true’ diversification in DNA libraries. In drug discovery, big numbers for screening campaigns are loved. Trillions of molecules! 1020‑member libraries! But there is a very real question to ask: how many distinct molecules can actually fit in a